Physician profile
Scott W Silodor
NPI 1053392258
$1,834.34
in general payments reported to CMS, 2019-2025
19 companies · $816 in 2025
The $816 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $261 · 2020: $130 · 2021: $117 · 2023: $229 · 2024: $282 · 2025: $816.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,327.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,326.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $281.31 | 2024-2025 | Envista Mx60 Iol, Envista Aspire Iol, Xiidra |
| Tarsus Pharmaceuticals, INC. | $281.12 | 2024-2025 | Xdemvy |
| Glaukos Corporation | $204.54 | 2025 | Idosetr |
| Biotissue Holdings INC. | $189.92 | 2023-2025 | |
| Sun Pharmaceutical Industries INC. | $179.80 | 2019-2025 | |
| Allergan, INC. | $144.94 | 2019-2021 | |
| Abbvie INC. | $110.93 | 2023-2025 | Alphagan P, Lumigan |
| Dompe US, INC. | $107.63 | 2023 | Oxervate |
| Alcon Vision LLC | $65.71 | 2020-2025 | Tryptyr |
| Novartis Pharmaceuticals Corporation | $51.90 | 2019-2021 | |
| Harrow Eye, LLC | $35.88 | 2025 | Vevye |
| Oyster Point Pharma, INC. | $32.60 | 2023-2024 | Tyrvaya |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $28.86 | 2019 | |
| Aerie Pharmaceuticals, INC. | $28.83 | 2019-2020 | |
| Shire North American Group INC | $27.92 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Omeros Corporation | $16.31 | 2019 | |
| Kala Pharmaceuticals, INC. | $16.30 | 2021 | |
| Johnson & Johnson Surgical Vision, INC. | $16.07 | 2019 | |
| Amgen INC. | $13.77 | 2024 | Tepezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Silodor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.